PMID- 18161770
OWN - NLM
STAT- MEDLINE
DCOM- 20080311
LR  - 20080102
IS  - 1527-6465 (Print)
IS  - 1527-6465 (Linking)
VI  - 14
IP  - 1
DP  - 2008 Jan
TI  - Human herpesvirus 6 infection in adult living related liver transplant 
      recipients.
PG  - 100-9
AB  - To analyze human herpesvirus 6 (HHV-6) infection in adult living related liver 
      transplantation, we performed a virological analysis, including viral isolation, 
      serological assay, and real-time polymerase chain reaction, of serially collected 
      blood samples from 67 recipients. In addition, cytokine levels were measured to 
      determine their role in viral reactivation. HHV-6 was isolated from only 4 
      recipients (6.0%), and viral DNA was detected in 15 (22.4%) of the 67 recipients. 
      A significant increase in HHV-6 immunoglobulin G antibody titers was observed in 
      19 (28.4%) of the 67 recipients. Finally, 26 recipients (38.8%) had HHV-6 
      reactivation 2-6 weeks after transplantation. HHV-6 associated clinical features 
      were analyzed in the 17 recipients presenting with either viremia or DNAemia. Two 
      recipients with viremia and 3 recipients with DNAemia had unexplained fever at 
      the time of viral infection. An increase in aminotransferase levels was observed 
      in 2 recipients with viremia and 3 recipients with DNAemia. Recipients with liver 
      cirrhosis caused by hepatitis B virus or hepatitis C virus infection as the 
      underlying disease were more likely to have HHV-6 infection (P = 0.025). 
      Mortality at the last follow-up in recipients with HHV-6 reactivation was 
      significantly higher than in those without viral reactivation (P = 0.0118). 
      Plasma interleukin-6 levels were significantly higher in the recipients with 
      HHV-6 viremia than in the recipients without viremia at 4 weeks post-transplant 
      (P = 0.0411). Moreover, tumor necrosis factor alpha levels were also higher in 
      recipients with HHV-6 viremia (P < 0.0001) or reactivation (P = 0.0011) than in 
      recipients without viremia or reactivation 4 weeks post-transplant.
CI  - (c) 2007 AASLD.
FAU - Ohashi, Masahiro
AU  - Ohashi M
AD  - Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, 
      Aichi, Japan.
FAU - Sugata, Ken
AU  - Sugata K
FAU - Ihira, Masaru
AU  - Ihira M
FAU - Asano, Yoshizo
AU  - Asano Y
FAU - Egawa, Hiroto
AU  - Egawa H
FAU - Takada, Yasutsugu
AU  - Takada Y
FAU - Uemoto, Shinji
AU  - Uemoto S
FAU - Yoshikawa, Tetsushi
AU  - Yoshikawa T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Liver Transpl
JT  - Liver transplantation : official publication of the American Association for the 
      Study of Liver Diseases and the International Liver Transplantation Society
JID - 100909185
RN  - 0 (Antibodies, Viral)
RN  - 0 (DNA, Viral)
RN  - 0 (Interleukin-6)
SB  - IM
MH  - Adult
MH  - Antibodies, Viral/analysis
MH  - DNA, Viral/analysis
MH  - Female
MH  - Fluorescent Antibody Technique, Indirect
MH  - Follow-Up Studies
MH  - Herpesvirus 6, Human/genetics/immunology/*isolation & purification
MH  - Humans
MH  - Immunoassay
MH  - Incidence
MH  - Interleukin-6/blood
MH  - Japan/epidemiology
MH  - Liver Cirrhosis/*surgery
MH  - Liver Transplantation/*methods
MH  - *Living Donors
MH  - Male
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Retrospective Studies
MH  - Roseolovirus Infections/blood/epidemiology/*virology
MH  - Viremia/epidemiology/virology
EDAT- 2007/12/29 09:00
MHDA- 2008/03/12 09:00
CRDT- 2007/12/29 09:00
PHST- 2007/12/29 09:00 [pubmed]
PHST- 2008/03/12 09:00 [medline]
PHST- 2007/12/29 09:00 [entrez]
AID - 10.1002/lt.21304 [doi]
PST - ppublish
SO  - Liver Transpl. 2008 Jan;14(1):100-9. doi: 10.1002/lt.21304.